Joinn Laboratories(China)Co.,Ltd. (HKG: 6127)

Market Cap	13.78B
Revenue (ttm)	2.35B
Net Income (ttm)	-1.01M
Shares Out	n/a
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	Jun 28, 2024

Volume	2,036,713
Open	9.68
Previous Close	9.59
Day's Range	9.58 - 10.24
52-Week Range	6.31 - 14.84
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 28, 2025

About Joinn Laboratories(China)Co.,Ltd.

Joinn Laboratories(China)Co.,Ltd. provides preclinical and non-clinical services in the United States, the People’s Republic of China, and internationally. It operates through three segments: Non-Clinical Studies Services; Clinical Trial and Related Services; and Sales of Research Models. The Non-Clinical Studies Services segment offers drug safety assessment, drug metabolism and pharmacokinetics studies, and pharmacology and efficacy studies. The Clinical Trial and Related Services segment provides clinical CRO services, co-managed phase I cli...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1995
• Employees: 2,510
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6127

Financial Performance

In 2023, Joinn Laboratories(China)Co.,Ltd.'s revenue was 2.38 billion, an increase of 4.78% compared to the previous year's 2.27 billion. Earnings were 396.99 million, a decrease of -63.04%.

Financial numbers in CNY